Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third Time Is Not A Charm For Merck's Bid To Expand Gardasil Use To Older Women

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA rejects broader indication for the HPV vaccine and revises labeling to include information about a lack of demonstrated efficacy in women older than 26.

You may also be interested in...



Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals

July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines

Gardasil Anal Cancer Indication Passes FDA Muster; Next Stop Is ACIP

Expanded indication does not actually expand the target population for the HPV vaccine, but the data should bolster Merck's argument for a routine vaccination recommendation in males when it goes before CDC's Advisory Committee on Immunization Practices.

Merck Looks To Mid-June FDA Decision On Expanded Use Of Gardasil To Older Women

Company unveils data at European conference supporting use in women ages 27 through 45; data was sent to FDA late last year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel